search
Back to results

Cephalic Phase in Anorexia Nervosa,Bulimia Nervosa and Obese Binge Eaters (Cephalic 1)

Primary Purpose

Anorexia Nervosa, Bulimia Nervosa

Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
chocolate cake
Sponsored by
Tel-Aviv Sourasky Medical Center
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional basic science trial for Anorexia Nervosa focused on measuring Cephalic phase, Anorexia nervosa, Bulimia nervosa, obese binge eaters, VAS, EDI, shame-feed procedure

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

75 patients will be divided into the following 4 subgroups;

  1. . 15 patients with anorexia nervosa.
  2. . 15 patients with bulimia nervosa (purging type).
  3. . 15 patients with binge eating disorder and obesity.
  4. . 15 obese patients without eating disorder
  5. . 15 Non-eating disordered normal weight patients.

Non diabetic and non-pregnant patients above 18 years of age without gastrointestinal diseases and without medications which can affect gastrointestinal motility and appetite.

Sites / Locations

  • TASMCRecruiting

Outcomes

Primary Outcome Measures

VAS, EDI, Blood test for glucose, insulin, PP, shame feed procedure

Secondary Outcome Measures

Full Information

First Posted
June 27, 2007
Last Updated
July 4, 2007
Sponsor
Tel-Aviv Sourasky Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT00493519
Brief Title
Cephalic Phase in Anorexia Nervosa,Bulimia Nervosa and Obese Binge Eaters
Acronym
Cephalic 1
Official Title
Cephalic Phase in Anorexia Nervosa,Bulimia Nervosa and Obese Binge Eaters
Study Type
Interventional

2. Study Status

Record Verification Date
April 2007
Overall Recruitment Status
Unknown status
Study Start Date
July 2007 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2007 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
Tel-Aviv Sourasky Medical Center

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objective of this trial is to examine the cephalic phase insulin response (CPIR) and pancreatic polypeptide (PP) release as indicators of the cephalic phase occurrence and magnitude to palatable food stimulus in anorectic and bulimic subgroups as compared to healthy controls
Detailed Description
Food stimulation of gastric and pancreatic secretion is classically divided into cephalic, gastric and intestinal phases. Cephalic phase refers to a simultaneous activation of gastrointestinal motility, gastric acid and pancreatic enzyme secretion ,as well as, release of hormones from the endocrine pancreas which occurs through activation of vagal -efferents as a result of food-related sensory stimuli such as taste and smell prior to nutrient absorption and which coincides with a thermogenic response. Of the cephalic phase secretions, cephalic phase insulin release (CPIR) has received the most attention, but pancreatic polypeptide (PP) and glucagon responses have also been studied. While the magnitude of cephalic phase insulin release is relatively small (25% above baseline), pancreatic polypeptide increases 100% above baseline. The large magnitude of the PP response makes it a sensitive indicator of vagal activation to food stimuli. In most experiments, subjects are either exposed to visual and olfactory stimulation by seeing and smelling the food stimulus or are required to perform a modified sham-feed, i.e. to taste, chew and then expectorate the food stimulus. In general, cephalic phase are thought to be preparatory response before ingestion of food. Because of their small magnitude, the physiological significance of the cephalic phase hormonal responses has been largely discounted. However, there is evidence that experimental prevention of CPIR lead to hyperinsulinemia and hyperglycemia. Therefore, CPIR may contribute to glucose homeostasis /regulation. Moreover CPIR may be an indicator of hunger and could be important for understanding eating disorders. In parallel with these hormonal secretion ,an increase in energy expenditure has also been observed . This thermogenic response to food is even greater with sham feeding than with normal feeding and is paralleled by changes in RQ showing enhanced carbohydrate oxidation. Studies conducted in obese humans demonstrate exaggerated absolute magnitude of CPIR .However basal hyper-insulinemia which is typically observed in obese individuals may clouds this observation. Moreover, it has been hypothesized that CPIR is attenuated in obese when is expressed as a percentage of baseline and therefore they may not secrete enough insulin during pre-absorptive period to regulate postprandial glucose levels. There is also evidence that obese people with insulin resistance have a reduced thermogenic response to feeding . Only limited numbers of studies have been done on the cephalic phase in anorexia and bulimia. There are findings of a significant CPIR in anorexics as compared to controls which tends to rule out a deficient cephalic insulin response as a contributor to the self-starvation observed in anorexia nervosa. As to bulimics who often show endocrine abnormalities, their CPIR was only slightly differ or from controls. These findings suggest more complex determinants of eating disorders than physiological state alone.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anorexia Nervosa, Bulimia Nervosa
Keywords
Cephalic phase, Anorexia nervosa, Bulimia nervosa, obese binge eaters, VAS, EDI, shame-feed procedure

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
75 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Procedure
Intervention Name(s)
chocolate cake
Primary Outcome Measure Information:
Title
VAS, EDI, Blood test for glucose, insulin, PP, shame feed procedure
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 75 patients will be divided into the following 4 subgroups; . 15 patients with anorexia nervosa. . 15 patients with bulimia nervosa (purging type). . 15 patients with binge eating disorder and obesity. . 15 obese patients without eating disorder . 15 Non-eating disordered normal weight patients. Non diabetic and non-pregnant patients above 18 years of age without gastrointestinal diseases and without medications which can affect gastrointestinal motility and appetite.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nachum Vaisman, Prof.
Phone
+972-524-266596
Email
vaisman@tasmc.health.gov.il
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nachum Vaisman, Prof.
Organizational Affiliation
TASMC Israel
Official's Role
Principal Investigator
Facility Information:
Facility Name
TASMC
City
Tel Aviv
ZIP/Postal Code
64239
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nachum Vaisman, Prof.
Phone
+972-524-266596
Email
vaisman@tasmc.health.gov.il

12. IPD Sharing Statement

Learn more about this trial

Cephalic Phase in Anorexia Nervosa,Bulimia Nervosa and Obese Binge Eaters

We'll reach out to this number within 24 hrs